Roche today announced the launch of Evrysdi (risdiplam), the first and only approved treatment in India for Spinal Muscular Atrophy (SMA) patients.
Evrysdi was first approved by the US FDA in August 2020 and is today available in India within 11 months of the US approval. Since its launch, over 4,000 SMA patients across 50+ countries have benefitted from Evrysdi.
This story is provided by PRNewswire.will not be responsible in any way for the content of this article. (ANI/PRNewswire)
( With inputs from ANI )
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor